Nano-X Imaging Ltd. Stock Price, News & Analysis

Nano-X Imaging announced FDA 510(k) clearance for its Nanox Cart X-Ray System on April 2, 2021, marking a significant milestone. The company aims to submit approval for its multi-source device later this year. Despite progress, shipment of 1,000 multi-source units originally scheduled for Q1 2022 will be delayed. The company ended Q1 2021 with $219 million in cash, up from $7.4 million net loss in Q1 2020. Increases in R&D and administrative expenses were noted, with a total net loss of $12.7 million for the quarter, compared to previous losses.

NANOX IMAGING LTD (NASDAQ: NNOX) appointed Moshe Shtengel as Chief Business Officer on May 2, 2021. With extensive experience in medical business development, Shtengel previously led sales and marketing at Tuttnauer and held key positions at Lumenis and Truphatek. His expertise is expected to enhance Nanox's commercial strategy as they prepare for the launch of their novel Nanox.ARC digital x-ray technology, which has received FDA clearance. The company aims to democratize medical imaging globally.

Nano-X Imaging Ltd (NASDAQ: NNOX) will announce its first quarter 2021 financial results on May 11, 2021, prior to market trading. A conference call will follow at 8:30 AM ET to discuss these results. The company focuses on innovative medical imaging technology, aiming to reduce costs associated with medical imaging systems. Founded by Ran Poliakine, Nano-X intends to collaborate with leading healthcare organizations for affordable imaging services. Further information is available on their website.

Nano-X Imaging Ltd (NASDAQ: NNOX) has filed its annual report on Form 20-F for the fiscal year ending December 31, 2020, with the SEC on April 6, 2021. The report includes audited consolidated financial statements, accessible on the SEC's website and Nano-X’s official site. The company emphasizes its mission to democratize healthcare through innovative medical imaging technology, which aims to make imaging services more affordable. Shareholders can request a hard copy of the report free of charge by contacting Investor Relations.

Nanox has announced its Nanox.ARC digital x-ray technology received 510(k) clearance from the FDA, a crucial milestone on its regulatory path in the US. The company plans to start system shipments in late 2021 and aims to deploy 15,000 systems by 2024, expanding accessibility to medical imaging globally. They also intend to submit an additional 510(k) application for their multi-source system in 2021, which could further enhance their commercial offerings.

NANO-X IMAGING LTD (NASDAQ: NNOX) announces that CEO Ran Poliakine will present at the Oppenheimer 31st Annual Virtual Healthcare Conference from March 16-18, 2021. His presentation is scheduled for March 17 at 10:40am ET and will be available via a live webcast. Interested parties can access the presentation through the company’s website, with a replay available for 90 days afterward. Nanox aims to transform medical imaging with affordable solutions, promoting early detection through collaborations with leading healthcare organizations.

Nano-X Imaging Ltd (NASDAQ: NNOX) reported its fourth quarter 2020 results, highlighting the successful demonstration of its Nanox.ARC at the RSNA Virtual Annual Meeting. The company plans to initiate product shipments in Q4 2021. As of Q4 2020, it held $213 million in cash, with no debt. However, the company reported a net loss of $19 million for the quarter and $43.8 million for the year. R&D expenses increased significantly, from $2.7 million in 2019 to $9.2 million, reflecting ongoing development efforts. The company aims to deploy 15,000 Nanox.ARC units globally by 2024.

NANO-X IMAGING LTD (NASDAQ: NNOX) will announce its Q4 and full year 2020 financial results on March 2, 2021, prior to market opening. A conference call and webcast will follow at 8:30 AM ET. The company focuses on developing an innovative digital X-ray source for medical imaging, aiming to reduce costs and improve access to imaging services. The management's forward-looking statements highlight anticipated risks such as regulatory compliance, technological feasibility, and potential disruptions from public health issues.

NANO-X IMAGING LTD (NASDAQ: NNOX) announced the pricing of its underwritten public offering of 3,091,635 ordinary shares at $62.50 per share, expected to close around February 16, 2021. Notably, the company will not sell any shares nor receive proceeds from this offering, as it involves non-officer, non-director shareholders. Cantor Fitzgerald & Co. and Oppenheimer & Co. are the lead managers for the offering. The SEC has declared the necessary registration effective, with final prospectus copies available through specified channels.